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Nedocromil Sodium and Adults 
Nine major, double-blind, controlled studies of the 
use of 4 mg nedocromil sodium administered via 
metered dose inhaler (MDI) to adults have been 
published in full since the first BTS Guidelines review 
(l-9) (see Table 1). The ages of the treated patients 
have ranged from 12 to 74 years. These studies have 
shown clinically and statistically significant effects 
of 4 mg nedocromil sodium on the daily symptoms. 
of asthma, pulmonary function and concomitant 
therapy. 
Adding 4 mg nedocromil sodium or placebo twice 
(1) or four times (2) a day to mild to moderate 
asthma patients exhibiting symptoms, although 
having access to p.r.n. inhaled and/or oral broncho- 
dilators [high dose (2)], led to significant improve- 
ments in asthma summary score, daytime asthma and 
sleep difficulty due to asthma, despite significantly 
reduced bronchodilator use. The changes in the 
symptom scores in the nedocromil-sodium-treated 
patients were such that they improved to scores lower 
than those recorded under the maintenance broncho- 
dilator regimen. Maintenance sustained release theo- 
phylline and oral and inhaled &-bronchodilators had 
been stopped 2 weeks before the study treatments 
commenced. 
In a similar study (3) in mild to moderate 
theophylline-dependent patients (except that the 
sustained release theophylline treatment was halved 
after 4 weeks of 4 mg nedocromil sodium or placebo 
twice daily and then removed completely after 6 
weeks), addition of nedocromil sodium gave signifi- 
cant improvements in day- and night-time asthma, 
morning tightness, cough, and day- and night-time 
inhaled bronchodilator use for most variables 
from the first period of assessment. Removal of 
theophylline therapy led to a gradual return of these 
variables to baseline levels in the nedocromil sodium- 
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treated patients, and a marked deterioration in the 
placebo-treated patients such that between-treatment 
differences were highly significant statistically. These 
and the following data suggest that 4 mg nedocromil 
sodium two to four times daily can provide 
equivalent-to-better control of asthma than regular 
and/or maintenance bronchodilator therapy. 
Double-blind, double-dummy comparisons of 
4 mg nedocromil sodium with a regular inhaled 
&bronchodilator (180-200 pug) four times daily (4,5) 
have shown significant improvements compared with 
the bronchodilator for day- and night-time asthma 
symptoms (4,5), morning chest tightness (5), and 
clinic assessment of daytime asthma, wheezing and 
shortness of breath (4). In a year-long, placebo- 
controlled, group comparison of 719 patients treated 
with 4 mg nedocromil sodium either twice or four 
times daily, depending on current therapy (broncho- 
dilators only or inhaled steroids, respectively), 
night-time asthma and daytime inhaled /$ use were 
significantly reduced throughout, coupled with im- 
provements in quality-of-life measures of health (6). 
Nedocromil sodium has also been shown to be 
effective in short-term use; adding 4 mg nedocromil 
sodium under double-blind, placebo-controlled, 
crossover conditions twice (7) or four times daily 
(7,8) to patients already on optimal high-dose inhaled 
steroid therapy (mean daily dose 1462 pug) or remain- 
ing symptomatic despite inhaled steroid and oral 
bronchodilator therapy, led to significant improve- 
ments in total (7) and nocturnal (8) symptom scores, 
cough and morning tightness alongside significantly 
reduced night-time inhaled &bronchodilator use 
(7,8). Supportive of these data, a phased steroid- 
reduction study (9) has shown nedocromil sodium to 
be of potential use in reducing high-dose inhaled 
steroid use. Patients requiring 2000,~g inhaled steroid 
daily reduced this usage by 31% (625pg daily) after 
receiving four times daily 4 mg nedocromil sodium 
compared with placebo. 
Compared with placebo or regular bronchodilator 
therapy (2-4,7), 4 mg nedocromil sodium given twice 
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Table 1 Details of double-blind, controlled studies in Table 2 Details of large-scale, placebo-controlled studies 
adults of the use of 4 mg nedocromil sodium administered in children of the use of nedocromil sodium administered 
via metered dose inhaler via metered dose inhaler 
Reference 
Nedocromil 
sodium 
(daily dose) 
Weeks of Number of 
treatment patients 
Nedocromil Age 
sodium Weeks of Number of range 
Reference (daily dose) treatment patients (years) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
4mgx2 8 112 
4mgx4 10 10 
4mgx2 8 3.5 
4mgx4 2x6 29 
4mgx4 12 212 
4mgx2 52 263 
4mgx4 456 
4mgx2 3x4 76 
4mgx4 
4mgx4 2x8 28 
4mgx4 22 69 
Meta-analysis 
11 
12 
13 
14 
15 
16 
4mgx4 12 209 Cl7 
4mgx3 8 120 6-19 
4mgx4 8 134 612 
4mgx4 12 234 611 
4mgx4 2x6 90 3-12 
4mgx2 6 120 6-12 
5mgx4 
(Intal) 
17 4mgx4 6 12 7-17 
18 4mgx3 16 15 
19 Review 
20 Review 
21 4mgx4 52 65 3-11 
(3,7) or four times a day (2,4,7) significantly 
improved mean daily peak expiratory flow, con- 
current with significant reductions in concomitant 
bronchodilator use. Significant improvements in 
diurnal variation in peak flow (4,5) and in bronchial 
hyper-responsiveness have also been demonstrated 
(4). These changes (4,5) were apparent during the first 
period of assessment. 
asthmatic patients maintained on bronchodilator 
therapy. 
Nedocromil Sodium and Children 
In the period since the publication of the BTS 
Guidelines, a meta-analysis of all double-blind, 
placebo-controlled clinical trials supplied and ana- 
lysed by Fisons (irrespective of positive or negative 
outcome or publication status) has been carried out 
(10). It is believed that, at the time of the analysis, no 
other source of inhaled nedocromil sodium and 
matching placebo was available, hence the analysis 
included all clinical trials - the only restriction being 
the exclusion of studies with less than nine patients 
per treatment group. Efficacy data from 4723 patients 
(2385, nedocromil sodium; 2338, placebo) were 
analysed by dose (4 mg twice or four times a day), by 
trial design and overall, and were presented as the 
difference (with 95% confidence limits) between 
nedocromil sodium and placebo of the change from 
baseline for day and night asthma, cough, peak 
expiratory flow rate, FEV,, inhaled bronchodilator 
use, and percent of patients reporting a very or 
moderately effective therapy. Overall, the analysis 
showed a highly significant effect of nedocromil 
sodium compared with placebo, for the two doses 
and for all efficacy variables. It was clear, however, 
that the clinical improvement with nedocromil 
sodium was greatest in the mild to moderate 
Six large-scale, placebo-controlled studies of the 
use of nedocromil sodium administered via MD1 
in children have been published since the first 
BTS Guidelines review (11-16) (see Table 2). Two 
studies have been published in full (11,12), and 
the remainder have been published as abstracts 
(13-16). The ages of the treated children ranged from 
3 to 19 years. 
Addition of 4 mg nedocromil sodium or placebo 
four times daily to the predominantly bronchodilator 
therapy of extrinsic asthmatic children (ll), led to 
significant improvements in total symptom score and 
daily inhaled bronchodilator use in the nedocromil- 
sodium-treated patients; symptom severity and 
bronchodilator use were halved in the nedocromil- 
sodium-treated children compared with negligible 
reductions in placebo-treated children. Similar results 
were apparent in an 8-week in-season study of 
ragweed-sensitive children also randomized to receive 
4 mg nedocromil sodium or placebo four times a day, 
with significant improvements in total symptom 
score, daytime asthma, morning asthma, daytime 
cough, sleep disturbance and salbutamol broncho- 
dilator use (13). 
Mild, episodic asthmatic children currently receiv- 
ing bronchodilator therapy had a significantly greater 
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percentage of symptom-free days, and significantly 
reduced total symptom (evident from the first period 
of assessment) and cough scores when treated with 
4 mg nedocromil sodium four times daily compared 
with placebo, despite the study taking place during 
a time of anticipated exposure to environmental 
triggers (14). In 90 asthmatic children who were 
either newly diagnosed or taking only bronchodi- 
lators as necessary, 4 mg nedocromil sodium four 
times a day delivered via a holding chamber device 
was again significantly more effective (total symp- 
toms, daytime symptoms, percentage of symptom- 
free days, and percentage of days using a 
&bronchodilator) than placebo (15). Interestingly, 
children previously well-controlled on 1540 mg 
sodium cromoglycate daily did not deteriorate 
when randomized to either 4 mg nedocromil sodium 
twice daily or 5 mg sodium cromoglycate four 
times daily, and showed no significant differences 
between treatment groups, suggesting a potential 
compliance advantage for nedocromil sodium (16). 
In placebo comparisons, when added to the 
current therapy of stable, mildly asthmatic children, 
4 mg nedocromil sodium three times daily led to 
significant improvements in FEV, and FVC, and 
a greater proportion of the children attaining nor- 
mal lung function (12), whilst a four times daily 
dose produced significant improvements in daily 
peak expiratory how, concurrent with a signifi- 
cant reduction in daily bronchodilator use (11). 
Bronchial responsiveness to histamine did not differ 
between groups in the former study (12), whereas 
two smaller studies showed 4 mg nedocromil 
sodium taken either three or four times daily signifi- 
cantly reduces non-specific bronchial responsiveness 
to ultrasonically nebulized distilled water and 
methacholine (17,18). 
A recent summary of the human safety data on 
nedocromil sodium indicated that it has an excellent 
safety profile, is well tolerated and that adverse 
events are generally mild (19). From the data then 
available (20) it was considered that nedocromil 
sodium was also well tolerated in children. Since 
then, data from an open, long-term safety study in 65 
chronic asthmatic children (21) who received 4 mg 
nedocromil sodium four times a day for 1 yr have 
shown excellent acceptability (fair-to-excellent in 
92%) with no withdrawals as a result of treatment, 
and an incidence and type of adverse event that 
was unremarkable (e.g. headache, cough and 
pharyngitis). These data are supportive of the 
findings from the individual clinical trials, and 
demonstrate that nedocromil sodium is well tolerated 
in children. 
Anti-inflammatory Activity of Nedocromil Sodium 
The anti-inflammatory activity of nedocromil 
sodium has been confirmed in man in vitro 
(20,22-24). Current pre-clinical research suggests that 
nedocromil sodium may act through an effect on 
chloride channels (25). Data published since the BTS 
Guidelines have confirmed an anti-inflammatory 
activity for nedocromil sodium in vivo in man, 
derived from clinical pharmacologic and therapeutic 
studies. To date, no studies of the anti-inflammatory 
activity of nedocromil sodium have been carried out 
in vivo in children. Recent research suggests, how- 
ever, that wheezing in children and asthma in adults 
may have common cellular mechanisms (26). 
Nedocromil sodium has been shown to inhibit the 
late asthmatic response when given before (27) and 
after the early response (28). Therefore, nedocromil 
sodium may affect this inflammatory response model 
of the airways irrespective of any mast-cell-driven 
effects. Nedocromil sodium inhibited the 48-h post- 
challenge infiltration of eosinophils into broncho- 
alveolar lavage (BAL) fluid of ragweed-allergic 
subjects (29), and restored post-challenge peripheral 
blood circulating eosinophil and basophil cell 
numbers towards normal (27). 
Bronchoalveolar lavage fluid eosinophil, neutro- 
phi1 and lymphocyte numbers, BAL fluid inflam- 
matory mediators and peripheral blood circulating 
eosinophil cell numbers were significantly reduced 
in adult atopic asthmatics after receiving 4 mg 
nedocromil sodium four times daily for 17 weeks 
(30). These findings were concurrent with significant 
improvements in cough, dyspnoea and sleep diffi- 
culty, and non-specific bronchial responsiveness to 
ultrasonically nebulized distilled water. In two simi- 
lar, controlled, four times daily dosing studies [a 
12-week placebo comparison (31) and a 16-week 
comparison with 200 pg salbutamol (32)], significant 
increases in morning and evening peak expiratory 
flow, and night-time bronchodilator use were pre- 
ceded by and concurrent with significantly reduced 
plasma protein leakage (31). Total and activated 
eosinophil numbers from bronchial biopsy increased 
in the salbutamol-treated patients and decreased 
in the nedocromil-sodium-treated patients, such 
that the between-active treatment differences were 
significant (32). 
Conclusion 
The clincal trials and clinical research data sup- 
port the conclusion that nedocromil sodium has an 
anti-inflammatory activity and, at a dose of 4 mg two 
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to four times daily, will be effective in the treatment 17. 
of mild to moderate asthma in adults and children. 
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